Description:

RTOG-0525 AE: Adverse Event Evaluation Form NCT00304031 Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FD9B3E8E-5C94-635F-E034-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FD9B3E8E-5C94-635F-E034-0003BA3F9857

Keywords:
Versions (4) ▾
  1. 8/26/12
  2. 1/9/15
  3. 1/9/15
  4. 7/8/15
Uploaded on:

July 8, 2015

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

RTOG-0525 AE: Adverse Event Evaluation Form NCT00304031

Radiation Therapy Oncology Group Phase III Lung Pre-Op Chemotherapy vs. Pre-Op Concurrent Chemoradiation for NSCLC

RTOG clinical trial administrative data
AMENDED DATA
Report All Continuing Or New Adverse Events
Type of corresponding form
CTCAE ATTRIBUTION CODE (Attribution to Protocol Treatment See protocol sections 6 & 7 for definition of "protocol treatment")
SAE report submitted